Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026
Rhea-AI Summary
Tactile Medical (Nasdaq: TCMD) will release fourth quarter and fiscal year 2025 financial results after the market closes on February 17, 2026. Management will host a conference call and Q&A at 5:00 p.m. ET the same day.
Dial-in details: 877-407-3088 (international 201-389-0927), access code 13758303. A live webcast and archived replay will be available at investors.tactilemedical.com and a phone replay for two weeks.
About Tactile Medical: the company develops at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TCMD declined 1.78%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TCMD slipped 0.45% while close peers showed mixed moves: CLPT up 3.36%, NPCE up 5.02%, SNWV down 0.82%, CBLL down 2.79%, and SENS flat. With no peers in the momentum scanner, this points to a stock-specific response to the earnings-date announcement.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 18 | Conference appearance | Neutral | -1.1% | Announcement of participation and fireside chat at a healthcare conference. |
| Nov 03 | Earnings report | Positive | +4.6% | Q3 2025 beat with 17% revenue growth and raised full-year guidance. |
| Oct 28 | Clinical data update | Positive | -1.1% | Six‑month trial data showing sustained benefits of Flexitouch Plus therapy. |
| Oct 20 | Earnings date notice | Neutral | +1.0% | Announcement of Q3 2025 earnings release timing and access details. |
| Aug 04 | Earnings report | Positive | +26.8% | Q2 2025 revenue growth, solid margins, and updated 2025 guidance. |
Recent earnings reports (Q2 and Q3 2025) with strong growth and guidance updates were followed by positive moves, while a positive clinical trial update saw a mild negative reaction, suggesting occasional divergence on clinical news but generally constructive responses to financial updates.
Over the last six months, TCMD has combined financial execution with clinical and investor-relations activity. Q2 2025 results showed revenue of $78.9M (+7.8% YoY) and Q3 2025 revenue of $85.8M (+17% YoY), with guidance raised and a new $25M repurchase authorization. A large 236‑patient trial supported Flexitouch Plus benefits, while conference and prior earnings-date announcements maintained engagement with investors. Today’s Q4/FY25 earnings-date notice fits this pattern of regular communication.
Market Pulse Summary
This announcement schedules Tactile Medical’s fourth quarter and fiscal year 2025 results for February 17, 2026, with a management conference call at 5:00 p.m. Eastern Time. In recent quarters, the company reported solid revenue growth and raised guidance, alongside clinical data supporting Flexitouch Plus. Investors may focus on how Q4 and full-year numbers compare with prior guidance, progress in at‑home therapy adoption, and any updates on capital deployment or repurchase activity disclosed on the call.
AI-generated analysis. Not financial advice.
MINNEAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2025 financial results will be released after the market closes on Tuesday, February 17, 2026.
Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 17, 2026, to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13758303. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13758303. The webcast will be archived at investors.tactilemedical.com.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com
FAQ
When will Tactile Medical (TCMD) release Q4 and FY2025 financial results?
How can investors join the Tactile Medical (TCMD) earnings call on February 17, 2026?
Where will the Tactile Medical (TCMD) earnings webcast and replay be hosted?
What time is the Tactile Medical (TCMD) conference call for the FY2025 results?
What therapies and conditions does Tactile Medical (TCMD) focus on?
